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3-{[3-(2-Chlorophenyl)-4,5-dihydro-5-thioxo-1H-1,2,4-triazol-1-yl] methyl}benzonitrile (AR-C133611XX 3 ; Fig. 1 ) is a CXCR2 receptor antagonist, which is being evaluated for its potential therapeutic utility. Preliminary in vitro studies followed by HPLC-MS analysis suggested the major metabolic route of AR-C133611XX was glucuronidation. However, the site of glucuronidation was uncertain. Many drugs are known to undergo glucuronidation either directly or following phase I metabolism (Miners and MacKenzie, 1991) . Glucuronidation reactions are catalyzed by the UDPglucuronyltransferase family of enzymes (Burchell and Coughtrie, 1989; Burchell et al., 1991; Miners and MacKenzie, 1991) located principally in the hepatic endoplasmic reticulum.
This report describes the characterization of the glucuronide of AR-C133611XX produced by incubation with isolated dog hepatocytes. The site of attachment of the glucuronide moiety was deduced from 1 H and 13 C NMR chemical shifts and 2D proton-carbon correlation experiments. Fully assigned proton and carbon data for this glucuronide are reported.
Materials and Methods
Chemicals and Reagents. AR-C133611XX (Baxter et al., 2000) was obtained from The Department of Medicinal Chemistry research compound bank at AstraZeneca R&D Charnwood (Loughborough, UK). Solvents for HPLC and HPLC-MS were of HPLC grade and were obtained from Fisher Scientific (Loughborough, UK). DMSO-d6 was purchased from Sigma-Aldrich (Gillingham, UK). Liver perfusion medium and liver digest medium were obtained from Invitrogen Ltd. (Paisley, UK). Suspension buffer was prepared from DMEM (1 liter powder equivalent, with 1 g/l glucose, with Na pyruvate, without NaHCO 3 , without phenol red) 2.2 g NaHCO 3 , 2.34 g Na HEPES, 2.0 g BSA fraction V, 0.4 g D-fructose (all Sigma-Aldrich) dissolved in 1 liter of distilled water and adjusted to pH 7.4 with 1 M HCl.
Isolation of Dog Hepatocytes. Dog hepatocytes were isolated by a modification of the two-step method of Seglen (1972) . A male beagle dog (12 kg) was humanely killed by intravenous administration of 150 mg/kg Euthatal (National Veterinary supplies, Stoke-on-Trent, UK). The vena cava was clamped above and below the liver. The hepatic portal vein was cannulated, and further clamps were applied to limit perfusion to the two smallest lobes on the lower right side of the dog. Drainage of perfusate was via a small puncture made in the vena cava. The liver was perfused first with liver perfusion medium and then liver digestion medium for 10 min each at a flow rate of 100 ml/min. The perfusate entering the hepatic portal vein was maintained at 40°C to counteract heat loss during passage through the liver. The liver was removed, and the tissue disrupted by cutting the capsule and gently scraping with a blunt spatula to release the cells. Cells were initially released into 50 ml of suspension buffer at room temperature with further additions of ice-cold suspension buffer to a final volume of 300 ml. Viable cells were pelleted by centrifugation at 50g, the supernatant removed, and the cells resuspended in ice-cold suspension buffer to 300 ml. The centrifugation/resuspension step was repeated and the cells resuspended to a final volume of 200 ml. Cell yield and viability was assessed by standard trypan blue exclusion methodology (2 ϫ 10 9 viable cells at 95% viability). Production and Isolation of Glucuronide Metabolite. Dog hepatocytes were diluted with suspension buffer to a cell density of 4 ϫ 10 6 viable cells/ml. The diluted hepatocytes were aliquotted into four plastic Sterilin pots (250-ml capacity; 25 ml of hepatocyte suspension per pot; Stone, UK). The pots were placed in a shaking water bath at 37°C, 80 oscillations/min, and incubated for 10 min. To each pot was added 5 aliquots of 50 l AR-C133611XX (3 mM in DMSO) with gentle mixing between each addition, giving a final concentration of 30 M AR-C133611XX. The incubation was continued for 120 min and then terminated by the addition of 50 ml of ethanol to each pot. Following centrifugation at 350g (20 min, 4°C), the supernatant was removed and the volume reduced to approximately 5 ml by centrifugal evaporation (60°C, overnight). This aqueous residue was subjected to analytical-scale purification by successive injections of 100 l onto the same HPLC system as used for HPLC-MS (see below). The eluate fractions corresponding to the glucuronide metabolite were combined and dried down by rotary evaporation to yield approximately 300 g of material for NMR analysis.
HPLC-MS. HPLC was carried out using an HP1100 chromatography system (Agilent Technologies, Stockport, UK). The chromatography method employed a Symmetry C 8 , 5 m, 50 ϫ 4.6 mm column fitted with a 15 mm C 8 guard column (both Waters, Watford, UK). Both columns were maintained at 40°C. Mobile phase A was methanol; mobile phase B was 0.025% (w/v) ammonium acetate. The gradient was initially 5% A, linear to 90% A over 7 min, switching to 100% A at 7.1 min, and holding at 100% A until 8.5 min then returning to initial conditions. Total flow rate was a constant 1.5 ml/min. Typical injection volume was 20 l. The reinjection time was 10 min.
The chromatography system linked to an HP1100 UV detector (300 nm) and thence to a Finnigan MAT TSQ7000 mass spectrometer (Thermoquest, Hemel Hempstead, UK) operating in atmospheric pressure chemical ionisation mode (vaporizer temperature, 550°C; capillary temperature, 250°C) or electrospray ionisation mode. Q1 was scanned from 160 to 900 amu (scan time, 1 s).
NMR. All samples and spectra were run on a 600 MHz Varian Unity Inova Spectrometer (Palo Alto, CA) using a 5-mm triple resonance probe at a probe temperature of 25°C. Samples of AR-C133611XX and the isolated glucuronide were dissolved in approximately 250 l of DMSO-d6 and placed into appropriate susceptibility-matched Shigemi microtubes (Shigemi Inc., Allison Park, PA). Proton, carbon, gradient-enhanced HSQC and gradient-enhanced HMBC spectra were acquired on both samples. Acquisition times for the glucuronide spectra were 4 min (proton), 15 h (carbon), 9 h (HSQC) and 59 h (HMBC). Referencing was to tetramethylsilane at 0.0 ppm for proton and to the solvent at 39.5 ppm for carbon. The 2D spectra were run at a limited carbon sweep width of 66 ppm about the aromatic region of the spectrum to improve resolution. The HSQC and HMBC experiments used standard library pulse sequences provided by the manufacturer. The evolution delay in the HMBC experiment was tuned to 62.5 ms, which optimizes long-range proton-carbon coupling constants of 8 Hz.
Results and Discussion

HPLC-MS.
The UV chromatogram of the purified AR-C133611XX glucuronide was free from nondrug-related interference
FIG. 2. Partial HMBC spectrum and structure of AR-C133611XX S-glucuronide
showing key long-range correlations to C7 and C9.
The crosspeaks shown are all due to three bond correlations with the exception of the residual 1 bond correlation from H1Ј to C1Ј(*). This is displaced (folded) from 87.7 ppm in the carbon dimension due to the limited sweep width used. and contained essentially two peaks. The major component eluted at 5.4 min and the minor component at 6.7 min. The retention time and mass spectrum of the later-eluting peak were identical to that of AR-C133611XX itself. The earlier-eluting peak was not present in a control sample taken from the original incubation at 0 min. Examination of the mass chromatograms revealed corresponding responses at 502 and 326 amu, respectively. The MS spectra across both peaks contained isotope patterns indicative of the presence of a chlorine atom, and the mass gain of 176 amu indicated that the peak at 5.4 min was a glucuronide of AR-C133611XX. NMR. It was necessary to use NMR to distinguish the proposed S-glucuronide from the two possible isomeric N-glucuronides. The chemical shifts of the anomeric proton and carbon are usually the key to determining the site of attachment of a glucuronide moiety. Comparison of the carbon chemical shifts of C1Ј of AR-C133611XX glucuronide with the few published examples shows good agreement [AR-C133611XX glucuronide, 87.7 ppm; 2-pyridinethiol-S-glucuronide, 84.1 ppm; N-oxide of this, 82.6 ppm (Jeffcoat et al., 1980) ; S-glucuronide metabolite of malotilate, 87 ppm (Nakaoka et al., 1989) ]. The proton chemical shift of the anomeric proton is significantly more shielded than in those S-glucuronides previously reported [AR-C133611XX glucuronide, 4.90 ppm; S-glucuronide metabolite of malotilate, 5.96 ppm (Nakaoka et al., 1989) ; S-glucuronide of 4-nitrothiophenol, 5.62 ppm (Smith et al., 1992) ]. However, the proton chemical shift would be expected to be more susceptible to ring current and solvent effects than the carbon chemical shift and is therefore less reliable as proof.
In view of the inconclusive nature of the proton and carbon chemical shifts described above, an alternative method of determining the site of glucuronide attachment was required. Since the central heterocycle is devoid of protons, proton-carbon correlation experiments were used. The HMBC experiment shows couplings between protons and carbons separated by two or three bonds. The spectrum for the glucuronide showed an intense long-range heteronuclear coupling between the glucuronide anomeric proton and a carbon at 149.1 ppm. This carbon also showed a correlation to the methylene protons (H12), proving its identity as C9; these correlations are shown in Fig. 2 . An additional correlation would be expected to C7 if the glucuronide was attached to N8 or N11, and the correlation between H1Ј and C9 would not be observed if the glucuronide moiety was attached to N11. This, then, is conclusive evidence that the glucuronide is attached to the sulfur atom.
Application of the one bond (HSQC) and long range (HMBC) correlation experiments allowed the full assignment of the proton and carbon spectra for both AR-C133611XX and the glucuronide; these data are shown in Table 1 . Interestingly, the methylene protons (H12) have become diastereotopic in the glucuronide due to the influence of the chiral center(s). Also, the heterocycle carbons C7 and C9 have moved with the formation of the glucuronide (by ϩ12.3 and Ϫ17.4 ppm, respectively) suggesting a change in the electronic nature of this ring.
We are aware of only a handful of reports of S-linked glucuronides in the literature: Lindsay et al. (1977) , Jeffcoat et al. (1980) , Bieder et al. (1983) , Nakaoka et al. (1989) , Peffer et al. (1991) , Bakke et al. (1992) , Smith et al. (1992) , and Fukuoka et al. (1995) . Of these reports, only the groups of Jeffcoat, Nakaoka, and Smith have described NMR data in support of their findings, although none give complete proton and carbon information.
Having obtained information on the precise site of metabolism of AR-C133611XX, synthetic effort was directed at substitution or replacement of the sulfur to access more metabolically stable compounds. Examples included methylation of the sulfur and replacement of the sulfur with oxygen or ϪNH 2 . These compounds were found to be highly stable, and no glucuronidation was detected. This example highlights the role of unambiguous metabolite identification in the drug discovery process and the power of NMR to this end. 
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